Suchergebnisse - "Zhang, Steven"

PubPharm (8)

1

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions : Exposure-Response Analyses of a Pivotal Phase I/II Study

enthalten in: Clinical pharmacology and therapeutics | 2022

von Gupta, N. | Largajolli, A. | Witjes, H. | +5

2

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

enthalten in: Cancer discovery | 2021

von Riely, G. | Neal, J. | Camidge, D. | +19

CommentIn: Cancer Discov. 2021 Jul;11(7):1617-1619. - PMID 34284994

3

Transcriptional profile of SH-SY5Y human neuroblastoma cells transfected by Toxoplasma rhoptry protein 16

enthalten in: Molecular medicine reports | 2016

von Fan, W. | Chang, S. | Shan, X. | +6

4

Toxoplasma gondii Rhoptry Protein ROP16 Mediates Partially SH-SY5Y Cells Apoptosis and Cell Cycle Arrest by Directing Ser15/37 Phosphorylation of p53

enthalten in: International journal of biological sciences | 2015

von Chang, S. | Shan, X. | Li, X. | +6

5

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

enthalten in: European journal of cancer (Oxford, England : 1990) | 2013

von Soria, J. | Baselga, J. | Hanna, N. | +14

6

Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants : assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations

enthalten in: Journal of clinical pharmacology | 2013

von Yang, Z. | Vakkalagadda, B. | Shen, G. | +7

7

Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects

enthalten in: Journal of clinical pharmacology | 2012

von Vakkalagadda, B. | Park, J. | Ahlers, C. | +6

8

Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans

enthalten in: Drug metabolism and disposition: the biological fate of chemicals | 2010

von Christopher, L. | Hong, H. | Vakkalagadda, B. | +11

1
[1]